Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

Li Shen, Roberto Pili

Research output: Contribution to journalArticlepeer-review

Abstract

Regulatory T cells (Tregs) represent a major obstacle of cancer immunotherapy. We reviewed here our discovery that Class I histone deacetylase (HDAC) inhibition can functionally target Tregs and help break the immune tolerance. We also discuss the effects of different classes of HDAC inhibitors on Tregs and the underline mechanisms, which may have a direct impact on designing cancer immunotherapy trials involving HDAC inhibitors.

Original languageEnglish (US)
Pages (from-to)948-950
Number of pages3
JournalOncoImmunology
Volume1
Issue number6
DOIs
StatePublished - Dec 1 2012

Keywords

  • Foxp3
  • HDAC inhibitors
  • Immunotherapy
  • Regulatory T cells
  • STAT3

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy'. Together they form a unique fingerprint.

Cite this